BiVictriX Therapeutics PLC Result of AGM (8207G)
March 31 2022 - 8:59AM
UK Regulatory
TIDMBVX
RNS Number : 8207G
BiVictriX Therapeutics PLC
31 March 2022
BIVICTRIX THERAPEUTICS PLC
("BiVictriX" or "the Company")
Result of Annual General Meeting
Alderley Park, 31 March 2022 - BiVictriX Therapeutics plc (AIM:
BVX), an emerging biotechnology company applying a novel approach
to develop next generation cancer therapies using insights derived
from frontline clinical experience, today announces that at its
Annual General Meeting, held today at 12.00pm, all resolutions were
duly passed.
For more information, please contact:
BiVictriX Therapeutics plc
Tiffany Thorn, Chief Executive Officer
Iain Ross, Chairman Email: info@bivictrix.com
SP Angel Corporate Finance LLP (NOMAD Tel: +44 (0) 20 3470
and Broker) 0470
David Hignell, Caroline Rowe (Corporate
Finance)
Vadim Alexandre, Rob Rees (Sales and
Broking)
Panmure Gordon (UK) Limited (Joint Tel: +44 (0) 20 7886
Broker) 2500
Rupert Dearden, Freddy Crossley, Emma
Earl
Tel: +44 (0) 20 3709 5700
Consilium Strategic Communications
Mary-Jane Elliott, Melissa Gardner, Email: Bivictrix@consilium-comms.com
Genevieve Wilson
About BiVictriX Therapeutics plc
BiVictriX is a UK-based drug discovery and development company
which is focused on leveraging clinical experience to develop a
class of highly selective, next generation cancer therapeutics
which exhibit superior potency, whilst eliminating
treatment-related toxicities.
The Company utilises a first-in-class approach to generate a
proprietary pipeline of Bi-Cygni(R) therapeutics which are designed
to selectively target antigen co-expression fingerprints, or "twin
antigens", on tumour cells, which are largely absent from healthy
cells. Whereas this concept has been validated in a clinical
diagnostic setting to support the diagnosis and monitoring of
haematological cancers, it has not yet been widely used in a
therapeutic setting.
BiVictriX has identified a diverse panel of novel
cancer-specific "twin antigens", across a broad range of cancer
indications including Diffuse Large B Cell Lymphoma, Acute Myeloid
Leukaemia and Blastic Plasmacytoid Dendritic Cell Neoplasm. The
Company is using these novel "twin-antigens" to develop more
effective and safer therapeutics to target cancers that are
expected to constitute orphan indications and currently constitute
areas of high unmet medical need.
Find out more about BiVictriX online at www.bivictrix.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGSDIFDFEESEID
(END) Dow Jones Newswires
March 31, 2022 09:59 ET (13:59 GMT)
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From Apr 2024 to May 2024
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From May 2023 to May 2024